American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
The recommendation of empagliflozin is based on evidence from the landmark EMPA-REG OUTCOME®trial, which investigated the effects of empagliflozin compared with placebo when added to standard of ......
